Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Electra D. Paskett(Ohio University), Kerry A. Rogers(The Ohio State University), Seema A. Bhat(The Ohio State University), James L. Fisher, Jacqueline C. Barrientos(Mount Sinai Medical Center), Ying Huang(The Ohio State University)
Cited by 19
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735